利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

23 条记录 (耗时 0.016 秒)

    Device for therapeutical treatment of a blood vessel
    1.
    发明授权
    Device for therapeutical treatment of a blood vessel 失效
    用于治疗血管的装置

    公开(公告)号：US06524333B1

    公开(公告)日：2003-02-25

    申请号：US09582676

    申请日：2000-08-17

    申请人： Jan Clarén ,  Stig Steen

    发明人： Jan Clarén ,  Stig Steen

    IPC分类号： A61F206

    CPC分类号： A61F2/82 ,  A61F2/958 ,  A61F2210/0052 ,  A61F2250/0067

    摘要： The invention relates to a device for therapeutical treatment of a blood vessel. It comprises in combination a stent, a balloon catheter for the insertion of the stent into a blood vessel, and a generator for generating ultrasound. The stent can be expanded radially and is of such construction that it is caused to vibrate and/or develop heat when exposed to ultrasound. Inserted into the blood vessel the stent can be expanded by means of the balloon catheter to engage the inside surface of the blood vessel in order to be left in the expanded condition as an inside lining in the blood vessel after the balloon catheter having been withdrawn from the blood vessel. Energy is transferred wirelessly by means of ultrasound generated by the generator, from an extra-corporeal position to the stent as located in the blood vessel engaging the inside surface thereof.

    摘要翻译： 本发明涉及一种用于治疗血管的装置。 其组合包括支架，用于将支架插入血管的气囊导管和用于产生超声波的发生器。 支架可以径向扩张，并且具有这样的结构，使得当暴露于超声波时使支架振动和/或发热。 插入到血管中，支架可以通过气囊导管扩张，以便在气囊导管已经从血管中取出之后与血管的内表面接合以便在扩张状态下作为血管内衬 血管。 能量通过发生器产生的超声波无线传送，从位于与其内表面接合的血管中的外部位置到支架。

    METHOD, DEVICE AND FLUID FOR TREATMENT OF A HEART AFTER HARVESTING
    2.
    发明申请
    METHOD, DEVICE AND FLUID FOR TREATMENT OF A HEART AFTER HARVESTING 审中-公开
    方法，设备和流体用于治疗心脏后收集

    公开(公告)号：US20120183945A1

    公开(公告)日：2012-07-19

    申请号：US13498155

    申请日：2010-09-22

    申请人： Stig Steen ,  Audrius Paskevicius

    发明人： Stig Steen ,  Audrius Paskevicius

    IPC分类号： A01N1/02

    CPC分类号： A01N1/0247 ,  A01N1/0226 ,  A01N1/0273

    摘要： Method and device for treatment of a heart after harvesting and before transplantation. The device includes a container intended to comprise the heart; a first line for connection to an aorta of the heart; a fluid circuit comprising an oxygenator for oxygenating said fluid and a heater/cooler for regulating the temperature of said fluid; and a pump for perfusion of said fluid through the coronary blood vessels of the heart. The fluid includes an oncotic agent exerting an oncotic pressure larger than about 30 mmHg; and is cardioplegic by comprising a potassium concentration, which is between 15 mM and 30 mM. A control device is arranged for controlling the pump to perform said perfusion intermittently, whereby the perfusion time is less than half of the cycle time. The perfusion is performed at a pressure, which is at least 15 mmHg and at least 15 mmHg lower than said oncotic pressure.

    摘要翻译： 收集后和移植前治疗心脏的方法和装置。 该装置包括旨在包括心脏的容器; 与心脏主动脉连接的第一条线 流体回路，包括用于使所述流体充氧的氧合器和用于调节所述流体的温度的加热器/冷却器; 以及用于通过心脏的冠状动脉血液灌注所述流体的泵​​。 流体包括施用大于约30mmHg的肿瘤压力的肿瘤剂; 并且通过包含在15mM和30mM之间的钾浓度来产生心脏停搏。 控制装置被布置成用于控制泵间歇地执行所述灌注，由此灌注时间小于循环时间的一半。 灌注在压力下进行，压力至少为15mmHg，并且比所述的起始压力低至少15mmHg。

    Evaluation and preservation solution
    3.
    发明授权
    Evaluation and preservation solution 有权
    评估和保存解决方案

    公开(公告)号：US07255983B2

    公开(公告)日：2007-08-14

    申请号：US10415740

    申请日：2001-11-05

    申请人： Stig Steen

    发明人： Stig Steen

    IPC分类号： A01N1/00 ,  A01N1/02

    CPC分类号： A01N1/0226 ,  A01N1/02 ,  Y10S514/832

    摘要： An evaluation and preservation solution for human and animal organs, tissues and parts thereof is described, wherein it comprises serum albumin at a concentration of 55-105 g/L, a scavenger and coating compound, preferably dextran compounds and derivatives thereof having essentially the same structure at a concentration of 1-55 g/L weight, and a physiological serum concentration of salts and nutrients in a physiologically acceptable medium.

    摘要翻译： 描述了人体和动物器官及其组织及其部分的评价和保存溶液，其中含有浓度为55-105g / L的血清白蛋白，清除剂和包衣化合物，优选葡聚糖化合物及其衍生物具有基本相同 浓度为1-55g / L的结构，以及生理学上可接受的培养基中盐和营养物质的生理血清浓度。

    MEDICAL FLUID, A METHOD OF TREATMENT AND USE OF THE FLUID
    4.
    发明申请
    MEDICAL FLUID, A METHOD OF TREATMENT AND USE OF THE FLUID 审中-公开
    医用流体，治疗和使用流体的方法

    公开(公告)号：US20130065218A1

    公开(公告)日：2013-03-14

    申请号：US13697839

    申请日：2011-05-13

    申请人： Stig Steen

    发明人： Stig Steen

    IPC分类号： A01N1/02

    摘要： A medical fluid for a harvested organ, tissue or parts thereof, for evaluation and/or preservation. The fluid includes cocaine or a stimulating analogue thereof; nor-adrenalin; and/or adrenaline. In addition, the fluid includes an oncotic agent, such as dextran; hormones, such as thyroxin; triiodotyronine; cortisone, insulin; and electrolytes and optionally nutrients in substantially physiological concentrations in a physiologically acceptable medium. In addition, the medical fluid further includes albumin in a concentration not exceeding 5.0%, and an oxygen carrier, such as erythrocytes. Further components may be dopamine; hydrocortisone; methylprednisolone; and a vasopressor agent, such as desmopressin. The cocaine; adrenalin; and noradrenaline are present in concentrations of each about 0.010 μM to 0.100 μM, for example in a ratio of 1:1:1.

    摘要翻译： 用于收获的器官，组织或其部分的用于评估和/或保存的医用流体。 流体包括可卡因或其刺激类似物; 肾上腺素; 和/或肾上腺素。 此外，流体包括肿瘤剂，例如葡聚糖; 激素，如甲状腺素; 三碘青ine碱 可的松，胰岛素; 以及在生理上可接受的介质中基本上生理浓度的电解质和任选的营养物质。 此外，药液还含有浓度不超过5.0％的白蛋白和红细胞等氧载体。 其他组分可以是多巴胺; 氢化可的松 甲泼尼龙 和血管加压素剂，如去氨加压素。 可卡因 肾上腺素 和去甲肾上腺素以每种约0.010μM至0.100μM的浓度存在，例如以1:1:1的比例存在。

    COMPOSITION COMPRISING NOR-ADRENALINE AND A NET INHIBITOR FOR ADMINISTERING TO A BRAIN-DEAD, HEART-BEATING POTENTIAL ORGAN DONOR
    5.
    发明申请
    COMPOSITION COMPRISING NOR-ADRENALINE AND A NET INHIBITOR FOR ADMINISTERING TO A BRAIN-DEAD, HEART-BEATING POTENTIAL ORGAN DONOR 审中-公开
    包含非 - 肾上腺素和网络抑制剂的组合物用于治疗脑死亡，心脏发生潜在有机组成

    公开(公告)号：US20110270215A1

    公开(公告)日：2011-11-03

    申请号：US13142727

    申请日：2009-12-30

    申请人： Stig Steen

    发明人： Stig Steen

    IPC分类号： A61M5/142 ,  A61K38/08 ,  A61P43/00 ,  A61K31/46

    CPC分类号： A61K31/46 ,  A01N1/0226 ,  A61K9/0019 ,  A61K31/135 ,  A61K31/137 ,  A61K31/198 ,  A61K31/55 ,  A61K31/573 ,  A61K38/095 ,  A61K45/06 ,  A61M5/142 ,  A61M5/172 ,  A61K2300/00

    摘要： A composition, an infusion solution, a method for treatment, and a kit for intravascular administration for treatment of a brain-dead, heart-beating, respirated, potential organ donor. The composition has a non-adrenaline and NET inhibitor for noradrenaline. The NET inhibitor may be cocaine or an analogue thereof or a tricyclic antidepressant. The composition may in addition include adrenaline, hydrocortisone, thyroxin, insulin, triiodotyronine, dopamine, a vasopressor agent, such as desmopressin, and methylprednisolone. The ratio between the NET inhibitor and nor-adrenaline is about 1:1. The composition may be dissolved in pure water, Ringer's acetate solution or physiological sodium chloride solution. The composition is infused in such an amount as to maintain a mean arterial pressure of about 60 mmHg. The composition may be infused by a pump at a rate of about 1.7 ml/hour decreasing dose-dependent to about 0.4 ml/hour after 24 hours.

    摘要翻译： 组合物，输液溶液，治疗方法和血管内给药用于治疗脑死亡，心跳，呼吸，潜在的器官供体的试剂盒。 该组合物具有用于去甲肾上腺素的非肾上腺素和NET抑制剂。 NET抑制剂可以是可卡因或其类似物或三环抗抑郁药。 组合物还可以包括肾上腺素，氢化可的松，甲状腺素，胰岛素，三碘青ron碱，多巴胺，血管加压剂，如去氨加压素和甲基强的松龙。 NET抑制剂与非肾上腺素之间的比例约为1:1。 组合物可溶于纯水，林格氏醋酸溶液或生理氯化钠溶液。 该组合物以维持约60mmHg的平均动脉压的量输注。 组合物可以以约1.7ml /小时的速率输注泵，24小时后剂量依赖于约0.4ml /小时。

    Evaluation and preservation solution
    6.
    发明授权
    Evaluation and preservation solution 有权
    评估和保存解决方案

    公开(公告)号：US08012677B2

    公开(公告)日：2011-09-06

    申请号：US11889460

    申请日：2007-08-13

    申请人： Stig Steen

    发明人： Stig Steen

    IPC分类号： A01N1/02

    CPC分类号： A01N1/0226 ,  A01N1/02 ,  Y10S514/832

    摘要： An evaluation and preservation solution for human and animal organs, tissues and parts thereof is described, wherein it comprises serum albumin at a concentration of 55-105 g/L, a scavenger and coating compound, preferably dextran compounds and derivatives thereof having essentially the same structure at a concentration of 1-55 g/L weight, and a physiological serum concentration of salts and nutrients in a physiologically acceptable medium.

    摘要翻译： 描述了人体和动物器官及其组织及其部分的评价和保存溶液，其中含有浓度为55-105g / L的血清白蛋白，清除剂和包衣化合物，优选葡聚糖化合物及其衍生物具有基本相同 浓度为1-55g / L的结构，以及生理学上可接受的培养基中盐和营养物质的生理血清浓度。

    Evaluation and preservation solution
    7.
    发明申请
    Evaluation and preservation solution 有权
    评估和保存解决方案

    公开(公告)号：US20080057488A1

    公开(公告)日：2008-03-06

    申请号：US11889460

    申请日：2007-08-13

    申请人： Stig Steen

    发明人： Stig Steen

    IPC分类号： A01N1/00

    CPC分类号： A01N1/0226 ,  A01N1/02 ,  Y10S514/832

    摘要： An evaluation and preservation solution for human and animal organs, tissues and parts thereof is described, wherein it comprises serum albumin at a concentration of 55-105 g/L, a scavenger and coating compound, preferably dextran compounds and derivatives thereof having essentially the same structure at a concentration of 1-55 g/L weight, and a physiological serum concentration of salts and nutrients in a physiologically acceptable medium.

    摘要翻译： 描述了人体和动物器官及其组织及其部分的评价和保存溶液，其中含有浓度为55-105g / L的血清白蛋白，清除剂和包衣化合物，优选葡聚糖化合物及其衍生物具有基本相同 浓度为1-55g / L的结构，以及生理学上可接受的培养基中盐和营养物质的生理血清浓度。

    Evaluation and preservation solution
    10.
    发明授权
    Evaluation and preservation solution 有权
    评估和保存解决方案

    公开(公告)号：US08980541B2

    公开(公告)日：2015-03-17

    申请号：US13178655

    申请日：2011-07-08

    申请人： Stig Steen

    发明人： Stig Steen

    IPC分类号： A01N1/02

    CPC分类号： A01N1/0226 ,  A01N1/02 ,  Y10S514/832

    摘要： An evaluation and preservation solution for human and animal organs, tissues and parts thereof is described, wherein it comprises serum albumin at a concentration of 55-105 g/L, a scavenger and coating compound, preferably dextran compounds and derivatives thereof having essentially the same structure at a concentration of 1-55 g/L weight, and a physiological serum concentration of salts and nutrients in a physiologically acceptable medium.

    摘要翻译： 描述了人体和动物器官及其组织及其部分的评价和保存溶液，其中含有浓度为55-105g / L的血清白蛋白，清除剂和包衣化合物，优选葡聚糖化合物及其衍生物具有基本相同 浓度为1-55g / L的结构，以及生理学上可接受的培养基中盐和营养物质的生理血清浓度。